Revefenacin received FDA approval on October 17, 2018 [1].
When was Revefenacin first approved by the FDA?
The U.S. Food and Drug Administration (FDA) approved revefenacin on October 17, 2018 [1].
What is Revefenacin used for?
Revefenacin is a medication used to treat overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency [1].
What is the mechanism of action for Revefenacin?
Revefenacin is a muscarinic receptor antagonist. It works by blocking the action of acetylcholine on muscarinic receptors in the bladder, which helps to relax the bladder muscle and reduce the involuntary contractions that cause urgency and incontinence [1].
What are the potential side effects of Revefenacin?
Common side effects of revefenacin include dry mouth, constipation, urinary tract infection, and upper abdominal pain [1].
What is the difference between Revefenacin and other OAB medications?
Revefenacin is a specific type of muscarinic receptor antagonist. Like other drugs in this class, it targets the same receptors in the bladder. However, individual responses and side effect profiles can vary between different medications [1].
When does patent protection for Revefenacin expire?
Information regarding the specific patent expiration dates for Revefenacin is not provided. DrugPatentWatch.com is a resource for tracking pharmaceutical patent information [2].